Clinical trials: COVID-19; Immunity
Intensive Care Unit, SARS-Cov-2
COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
Infection with the SARS-CoV-2 coronavirus (COVID-19) has recently been identified as a pandemic due to the speed and global scale of its transmission.
- Trial name
- RICO (NCT04392401)
- Testing
- Collection of blood samples in order to create a biocollection
- Where
- 8 sites in France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Genetic Predisposition
Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach
Reaction of the immune system and the body to a Coronavirus-19 (COVID-19) vaccination is so different and ultimately unpredictable has not yet been clarified.
- Trial name
- COVID 19-VAC (NCT04873128)
- Testing
- Multi-OMICS
- Where
- Germany
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Sarcoidosis, SARS-CoV2 Infection
Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis
People with sarcoidosis, particularly those with significant lung and/or cardiac involvement, who become infected with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) are likely at increased risk of complications or…
- Conditions
- Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
- Trial name
- NCT05089565
- Testing
- Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Northwestern University
SARS-CoV-2 Infection, Influenza Viral Infections
Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after…
- Conditions
- SARS-CoV-2 Infection, Influenza Viral Infections, Virus Shedding, Mucosal Immunity
- Trial name
- MIViral (NCT05794412)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
COVID-19
Immune Profiling of COVID19-patients Admitted to ICU
SARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019.
- Trial name
- IMPROVISE (NCT04473131)
- Testing
- No intervention
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Certain Disorders Involving the Immune Mechanism
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
The pandemic associated with the SARS-CoV-2 coronavirus has affected over 760 million individuals worldwide, resulting in more than 6.9 million deaths.
- Trial name
- MUCOVID (NCT06142279)
- Testing
- Sampling, PCR (polymerase chain reaction) SARS-CoV-2
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
COVID-19
COVID Booster in Pregnancy and Lactation
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
- Trial name
- NCT05543993
- Testing
- Bivalent COVID-19 Booster
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
COVID-19, Vaccination
COVID-19 Vaccination AZV 2021-2023
The study is aimed at the clinical and laboratory characteristics of patients with completed vaccination against SARS-CoV-2 admitted to the hospital in the standard ward and intensive care unit due to the severe course of…
- Conditions
- COVID-19, Vaccination, Immunity, Respiratory Failure
- Trial name
- NCT05589233
- Testing
- Vaccionation eighter started or full course
- Where
- Czechia
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Hradec Kralove
COVID-19, Coronavirus Infections
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
The goal of this clinical trial is to assess the immunogenicity, efficacy and safety of the Convacell vaccine in healthy adult volunteers aged 18 years and older.
- Conditions
- COVID-19, Coronavirus Infections, Respiratory Tract Infections, COVID-19 Respiratory Infection
- Trial name
- NCT05726084
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 6 sites in Russia
- Volunteers
- 16,304 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
COVID-19
Immunosuppression and COVID-19 Boosters
It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected.
- Trial name
- NCT05415267
- Testing
- diphtheria and tetanus toxoids (adsorbed) vaccine, COVID-19 vaccine
- Where
- 5 sites in Australia
- Volunteers
- 320 people
- Sponsor
- Kirby Institute
Cancer
Responses to COVID-19 Vaccination in Patients With Cancer
This is an observational study that will prospectively record and monitor responses and clinical outcomes of patients with cancer after covid-19 vaccination, including measurements of antibody titers in serum and also record…
- Trial name
- ReCOVer (NCT04745377)
- Testing
- IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
- Where
- Greece
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Hellenic Cooperative Oncology Group
SARS-CoV-2, COVID-19
A Study of Immune Responses to the Virus That Causes COVID-19
The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- CoVPN 5001 (NCT04431414)
- Testing
- Sample collection
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 953 people
- Sponsor
- COVID-19 Prevention Network
Covid19, Chronic Kidney Disease 5D
Immune Response in Dialysis Patients Vaccinated Against COVID-19
This is a prospective cohort study aimed to evaluate short- and mid-term immune response after SARS-CoV-2 vaccination using Gam-COVID-Vac (Sputnik V) vaccine in dialysis patients compared to the control group (medical staff).
- Trial name
- Sputnik-HD (NCT04805632)
- Where
- Russia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Saint Petersburg State University, Russia
COVID-19, Breakthrough Infection
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific antibody and neutralizing antibody level induced by adenovirus vector vaccines were lower than mRNA vaccines.
- Trial name
- NCT05132855
- Testing
- BNT162b2, mRNA-1273, MVC-COV1901
- Where
- Taiwan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
COVID-19 Vaccination, Gut Microbiota
Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts
This study aims to examine the association between gut microbiota composition and the magnitude and duration of immune response in subjects who have received different COVID-19 vaccines in Hong Kong and to identify the…
- Trial name
- NCT04980560
- Where
- Hong Kong
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Cancer
Vaccination Against COVID-19 in Cancer
This study will collect information on immune response and adverse events after vaccination against coronavirus disease (COVID-19) in a vulnerable patient cohort.
- Trial name
- VOICE (NCT04715438)
- Testing
- mRNA-1273 SARS-CoV-2 vaccine from Moderna
- Where
- 3 sites in Netherlands
- Volunteers
- 791 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
SARS-COV-2 Infection
Transplacental Transmission of COVID-19
SARS-CoV-2, the agent responsible for pandemic COVID-19 infection, is transmitted mainly by respiratory droplets. Regarding maternal-fetal transmission, even if the mode of transmission from mother to fetus is not clear, some…
- Trial name
- NCT05124574
- Testing
- Samples concern SARS-COV-2 + pregnant women at the time of childbirth, Samples concern newborns of SARS-COV-2 + mothers at birth
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Covid19, Non-specific Effects of Vaccines
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Background: The virus SARS-CoV-2 has spread rapidly throughout the world. Seniors are at high risk of severe COVID-19 when infected.
- Conditions
- Covid19, Non-specific Effects of Vaccines, Heterologous Immunity, Morbidity
- Trial name
- NCT04542330
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project